Envisia Therapeutics Precisely Engineering the Future of Ophthalmology™ April 2015 Corporate Milestones • Company formed in Nov 2013 as a spin out of Liquidia Technologies--$25m in funding • IND filed for ENV515, a 6 month biodegradable formulation for glaucoma – Ph 2a underway • Initiated development of ENV905, a biodegradable formulation for post cataract inflammation (IND expected 2H’15) • Developed XR formulations of biologics – assessing several partnership opportunities • Appointed Dr. Adrienne Graves and Dr. Gary Phillips to Board of Directors © ENVISIA Therapeutics– All Rights Reserved 2 Envisia Therapeutics Pipeline 2014 2015 2016 2017 2018 ENV515 (glaucoma) Pre-clinical Ph 2a Ph 3 Ph 2b ENV905 (post cataract inflammation) Research Pre-clinical Ph 2 Ph 3 NDA Partnership (back of the eye) Research Research Collaborations Product Development © ENVISIA Therapeutics– All Rights Reserved 3 PRINT® Technology Platform • Engineering and production of <100 nm particles to >1000 micron implants • cGMP manufacturing with high batch-to-batch reproducibility and dose uniformity • Manufacturing scale capable of supporting commercial demand cGMP Manufacturing Best in class control over particle size, shape and formulation © ENVISIA Therapeutics– All Rights Reserved 4 Precisely Engineered Ophthalmic Drug Delivery Systems Travoprost Difluprednate 0.5 mm High Concentration Bevacizumab Particles 5 µm Dexamethasone 0.5 mm Bevacizumab Microparticles in a Polymer Hydrogel 5 µm 0.5 mm PEG Hydrogel/RNA Nanoparticles 1 µm Versatile technology, compatible with a wide range of polymers, small molecules and biologics © ENVISIA Therapeutics– All Rights Reserved 5 Intracameral Biodegradable Formulations Glaucoma—ENV515 ENV515 Intracameral Extended-Release • • • • • • Target Product Profile 24/7 control of IOP (25-30% decrease) 6 month duration of action Less hyperemia than drops Easy administration Fully biodegradable Excellent safety Large Small Travoprost Extended-release biodegradable travoprost formulation puts the treatment of the disease in the hands of the doctor, not the patient © ENVISIA Therapeutics– All Rights Reserved 7 8 Months of IOP Reduction in Hypertensive Beagle Dogs Baseline Placebo ENV515 ENV515 30% change from baseline 32% reduction in baseline IOP over 8 months from single dose of ENV515 © ENVISIA Therapeutics– All Rights Reserved 8 Phase 2a Study Underway Phase 2a safety, efficacy, and ocular PK in glaucoma patients about to undergo cataract surgery: 20 patients, 4 weeks , 4 dose groups, TRAVATAN Z in non-study eye, IOP at several time points, ocular PK in aqueous humor and travoprost content in ENV515 retrieved during cataract surgery Phase 2a 1. PGA Washout Period (4 weeks) 2. Masked ENV515 Dosing Period (4 weeks) • 20 patients enrolled • All PGA therapy discontinued 3. Safety Follow-up Period (2 weeks) • All patients • 4 ENV515 dose groups (5 patients per dose group, 20 patients total) IOP IOP Initiate PGA washout Dose ENV515 IOP IOP IOP Recover ENV515 during cataract surgery (PK in aqueous humor and travoprost content in recovered ENV515) © ENVISIA Therapeutics– All Rights Reserved 9 Subconjunctival Biodegradable Formulations Ocular Inflammation—ENV905 ENV905: Post Cataract Difluprednate XR Current Situation • Topical steroids are QID dosing • Generics dominate, but branded products are competitive • Need for improvement in overall efficiency of managing cataract patients from beginning to end • • • • • Target Product Profile 3-4 week control of inflammation Lower drug exposure Easy administration Fully biodegradable Excellent safety Difluprednate 0.5 mm XR steroid formulation puts control of inflammation in the hands of the doctor © ENVISIA Therapeutics– All Rights Reserved 11 ENV905 is Efficacious for More than 3 Weeks in Rabbit Model of Inflammation Placebo ENV905 dosed at day 1, with sustained efficacy over 3 weeks Durezol ENV905 ENV905 in subconjunctival space immediately post-dose. Single dose ENV905 is equivalent or superior to daily topical QID Durezol® in vivo © ENVISIA Therapeutics– All Rights Reserved 12 Intravitreal Biodegradable Drug Delivery Back of Eye Diseases Extended Release Formulation Strategies Solid-state antibody or small molecule (0.1-5 mm) Material design High conc. mAb Micronized API Biodegradable Thermoplastics Degradable Hydrogels Microparticles Rods Extended release depot (10’smm-mm) PRINT creates multiple kinds of patentable size/shape/polymer combinations designed for multi-month delivery of biologics and small molecules © ENVISIA Therapeutics– All Rights Reserved 14 In-vivo Efficacy & Safety Proof-of-Concept Achieved Retinal Leakage Scores (rabbits at 2 months) Positive control 2 Formulation G 3 Negative control R e t in a l L e a k a g e S c o r e 4 Formulation G 1 50 F o r m u la tio n G G . rm l F o o s tr o n P o C o g tr e n N o C % B e v a R e le a s e d l a 6 Months in-vitro release 100 it ti iv v e e 0 Pilot safety and tolerability in nonhuman primate of vehicle and bevacizumab formulation shows good tolerability at 2 months 0 0 50 100 150 T im e ( D a y s ) Signed collaboration with market validating partner Other discussions ongoing Herlihy et al. 2014: ARVO Poster © ENVISIA Therapeutics– All Rights Reserved 15 New Technology Development Combination Products Demonstrated extended release from two different drugs in one release depot formulation Drug B Drug A Polymer 100 D ru g A Extended Release Combination Formulations % D r u g r e le a s e d 80 D ru g B 60 40 20 0 0 50 T im e ( D a y s ) © ENVISIA Therapeutics– All Rights Reserved 100 17 Engineered Nanoparticles for Drug Delivery 900 M a r k e te d P r o d u c t 850 P 1 - a n io n ic 500 P 2 - c a tio n ic P 3 - c a tio n ic 400 P 4 - c a tio n ic 300 200 100 in m 0 6 0 m in 0 3 r e l. m a s s d r u g in te a r s Particles can be used to study the effects of size, shape, chemistry and modulus for improving PK/PD properties © ENVISIA Therapeutics– All Rights Reserved 18 THANK YOU [email protected]
© Copyright 2024